ISMH – dedicated to the unmet need of improving men’s health
The International Society of Men’s Health (ISMH) is the only international organisation dedicated to the rapidly growing field of men’s health. The comprehensive scope of men’s health brings together multiple disciplines such as urology, cardiology, endocrinology, oncology, gerontology, psychiatry, psychology, sexual and reproductive medicine, public health and others.
Save the date: Men’s Health World Congress 2013; December 6-8, Washington DC
March 28, 2013
The ISMH is please to announce that the 9th Men’s Health World Congress (MHWC) will be held for the first time in the USA on December 6 to 8, 2013. The 2013 MHWC will be jointly conducted by our International Society of Men’s Health and the newly-launched American Society of Men’s Health.
This meeting will bring together all those interested in men’s health including multidisciplinary international groups of clinicians, academicians, researchers, key opinion leaders as well as professionals from the healthcare industry, medical education, health policy and others. The 2013 MHWC will feature the latest science and progress in men’s health, new advances in early and late stages of prostate cancer, cardiovascular disease, hypogonadism, infertility, endocrinology, psychiatry and others.
The meeting program will present lectures by top experts from around the globe, debates and interactive sessions on controversial clinical topics and much more! In addition, specialized symposia will address contemporary important issues in men’s health. The scientific program is designed by a multidisciplinary internationl committee of world-renouned experts and the 2013 MHWC is co-chaired by Alan Wein, Joel Heidelbaugh and Mikio Namiki.
Visit www.mhwc2013.org to receive further information !
Latest Update on Prostate Cancer Screening at the AUA Meeting, May 2013
May 13, 2013
At the American Urological Association Annual Meeting earlier this week, new guidelines from the AUA now recommend that men aged 55 to 69 who are considering prostate cancer screening discuss the benefits and potential harms of screening with their doctors, then to proceed based upon personal values and preferences. This recommendation is based upon high-quality evidence that suggests the screening benefit over 2- to 4-year intervals would allow 1 man per 1,000 to avert death from prostate cancer over a decade, yet the benefit extrapolated over a man's lifetime may actually be greater.
The AUA guidelines state that screening for prostate cancer in men less than 40 years of age is not recommended, nor is routine screening in men 40 to 54 years of age at average risk. To reduce harms of screening, a screening interval of 2 years may be preferable over annual screening in low-risk men who have engaged in shared-decision making with their physician. Lastly, routine prostate cancer screening in men over 70, or in men with a less than 10- to 15-year life expectancy is not recommended.
Reference: American Urological Association Annual Meeting, May 4-8, 2013, San Diego, California, USA